We’re proud to be named to the inaugural TIME 100 Companies Industry Leaders list for 2026. Being named one of the 10 Most Influential Health and Life Science Companies of 2026 is a profound honor. Coinciding with the anniversary of the biotech industry’s founding this month, this recognition reinforces our 50-year legacy of scientific leadership. It highlights our relentless curiosity and our commitment to delivering breakthroughs that transform patients’ lives for the next 50 years and beyond. http://spr.ly/6042BBRwP2 #TIME100CompaniesIndustryLeader #TheOriginalBiotech
About us
About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or patientinfo@gene.com. Community Guidelines: 1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.
- Website
-
http://www.gene.com
External link for Genentech
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- South San Francisco, California
- Type
- Privately Held
- Founded
- 1976
- Specialties
- Oncology, Immunology, Disorders of Tissue Growth and Repair, Neuroscience and Infectious Disease, Metabolism, and Ophthalmology
Locations
-
Primary
Get directions
1 Dna Way
South San Francisco, California 94080, US
-
Get directions
1000 New Horizons Way
Vacaville, California 95688, US
-
Get directions
1 Antibody Way
Oceanside, California 92056, US
-
Get directions
4625 NE Brookwood Pkwy
Hillsboro, Oregon 97124, US
Employees at Genentech
Updates
-
At the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting we’re presenting key real-world, product and pipeline data from our ophthalmology portfolio, emphasizing our commitment to advancing care for people living with wet age-related macular degeneration and diabetic macular edema. Learn more: http://spr.ly/6041BBP2Cl #ARVO2026
-
Neuropathologist Jeffrey Hofmann takes us #InTheLab, using new technologies to reveal how cells contribute to the loss of myelin, the protective sheath around nerve fibers that helps conduct electrical signals between neurons. These insights are helping scientists better understand the underlying causes of multiple sclerosis and identify the most promising targets to help slow or stop disease progression. Want to learn more? Listen to S7E02 of our podcast, Two Scientists Walk Into a Bar. http://spr.ly/6044BB3jDk
In the Lab: Take a look inside multiple sclerosis on a cellular level
-
We heard 2016 was trending… At the American Academy of Neurology Annual Meeting, we surprised members of our neuroimmunology team with their photos from 2016 and asked them to reflect on the progress of the past decade—and what the next 10 years may bring in multiple sclerosis (MS). Their reactions offer a glimpse into our MS research journey. Driven by purpose, inspired by the patient community, and continuously evolving. Hear from Erik Lundgren, MBA, Eugene An and Ashish Pradhan as they share perspectives on where we were, where we are, and where we’re headed in MS research and development. #AANAM #Neurology #MultipleSclerosis
Reflecting on a Decade of MS Research
-
We’re bringing more attention to diabetic macular edema (DME), an often overlooked eye condition associated with diabetes that impacts vision, and disproportionately affects Black adults. We’re proud to introduce All Eyes on DME, an initiative focused on raising awareness and supporting people living with diabetes in prioritizing their vision care. Learn more: http://spr.ly/6044BB1fxe
-
Advancing understanding in rare diseases like myelin oligodendrocyte glycoprotein antibody disease (MOGAD) requires continued research and collaboration. Julia Lefelar, co-founder and Executive Director of The MOG Project, shares why this work matters for the MOGAD community. #MOGADAwarenessMonth #AANAM
-
#Breaking: We are excited to share positive results from our Phase III trials evaluating our investigational BTK inhibitor in people living with relapsing multiple sclerosis (RMS). For the more than 2.9 million people living with multiple sclerosis (MS) worldwide, this data brings our research and development strides into focus, representing a potential new approach to MS with comprehensive disease control. Learn more: http://spr.ly/6046BB8uD8
-
#Breaking: Today at #AANAM we’re presenting the first-ever positive Phase III results in myelin oligodendrocyte glycoprotein antibody disease (MOGAD), a rare and debilitating autoimmune disease of the central nervous system. http://spr.ly/6048BBBmyE
-
The FDA accepted our supplemental Biologics License Application for our medicine to treat systemic lupus erythematosus (SLE). SLE, the most common form of #lupus, is a potentially life-threatening autoimmune disease affecting more than 3 million people worldwide. There’s a critical need for a treatment option that can help reduce the daily impact of the disease on patients and has the potential to reduce steroid use. If approved, our medicine has the potential to offer an option to manage this disease. Learn more: http://spr.ly/6049BBBrYT
-
In multiple sclerosis (MS), immune-driven inflammation plays a central role in how the disease progresses over time. Advancing our understanding of this biology is critical. BTK inhibitors are being studied for their potential to more precisely target this underlying immune activity, with the goal of helping preserve brain function across forms of MS. Learn more about our scientific approach: http://spr.ly/6047B6ApVd
Addressing the Biology of MS Progression